Cancer Research

OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH



March 1, 1993
Volume 53 • Number 5
PP. 937–1212
ISSN 0008-5472 • CNREA 8

Oncogene Science:

The SOURCE™ for Proven Methods and Expert Applications Support!

Specifically Tested for...

TGFα in Giant Nevus



c-jun in colon adenocarcinoma



Differentiation of ras Asp-12 using Mutation -Specific Antibody

P-Glycoprotein

LDL – R

HSP 72/73

All shown with trp E negative control

Paraffin Section Staining

Western Blotting

Immuno–precipitation

Cellular Staining



p53 in transfected SV80 cells



Cytokeratin in T–24 cells

Southern Hybridizations



Southern blots using various 40 mer DNA probes

Leukemia Phenotyping

Non-isotopic bcl-2 system for detection of translocations in follicular lymphoma



FDA approved TransProbe-1® kit for detection of Philadelphia (Ph ') translocation in CML

Our name might give you the impression that we specialize only in oncogenes. As you can clearly see, our product line goes well beyond oncogenes. **And even this extensive listing is only a fraction of our total line!** We have cytoskeletal protein products, hemopoietic factor products, cytokines, interleukins, DNA tumor virus antibodies, cell adhesion antibodies, cardiovascular reagents, and products for neuroscience research. If you don't see what you need for your research, just give us a call at **800-662-2616** from anywhere in the continental US (NY included) or at **516-222-0023** from outside the US.

The SOURCE™

for *over* 1,000 Antibodies, Probes, ELISA's, and the Reagents to Make Them Work!

PS=Paraffin Sections | WB=Western Blotting | IP=Immunoprecipitation | CS=Cellular Staining | SH=Southern Hybridization

Cell Cycle Products

- Cyclin A — WB IP
- Cyclin B_1 — WB IP
- p-13^{suc-1} — IP
- PCNA — PS WB IP CS SH
- p34^{cdc-2} — WB IP CS
- *raf*-1 — WB IP
- PSTAIRE — WB IP CS
- Protein Kinase C — WB SH

Signal Transduction

- Phosphotyrosine — PS WB IP CS
- *src* — WB IP CS Enzyme
- *fyn* — CS
- c-*abl* — WB IP CS SH
- PTPases — WB IP SH
- *trk* — IP

Transcription Factors

- c-*fos* — PS WB IP CS SH
- c-*jun* / AP–1 — PS WB IP CS SH
- *jun* B — WB IP SH
- c-*myc* — WB IP CS SH
- N *myc* — WB IP CS SH

All products except TransProbe–1® are for research use only. Not for use in diagnostic or therapeutic procedures.

p53/Tumor Suppressor Genes

- p53 wild-type — IP CS
- mutant — WB IP CS ELISA
- pantropic — PS WB IP CS SH ELISA
- Rb — WB IP SH
- DCC — *Coming Soon!*
- APC — *Coming Soon!*
- Wilm's — *Coming Soon!*

Oncogenes

- erb-B2 (neu) — PS WB IP CS SH ELISA
- v-H-*ras* — PS WB IP CS SH
- c-H-*ras* — PS WB IP CS SH
- c-K-*ras* — PS WB IP CS SH
- c-N-*ras* — PS WB IP CS SH
- pantropic *ras* — PS WB IP CS SH
- Mutation–Specific *ras* Antibodies — Asp-12, Arg-12, Glu-12, Val-12
- ELISA — *Coming Soon!*

Growth Factors / Receptors

- TGFα — PS WB CS SH ELISA
- TGFβ — IP WB SH
- bFGF — WB SH
- PDGF — SH
- EGF — PS WB IP SH ELISA
- EGF-R — PS WB IP CS SH ELISA
- NGF-R — IP CS SH
- Insulin — SH
- Insulin-R — IP SH
- IGF-I — IP SH
- IGF-I-R — IP CS SH

Call for more information– 1-800-662-2616

NEW

SH2 Domains *src*, PLCγ, p85
agarose & western blotting reagents

Quantitative ELISA's
TGFα, EGF-R, pantropic p53

Phosphatases 1B & T Cell

Oncogene Science™

106 Charles Lindbergh Blvd. Uniondale, NY 11553

Western Blotting=WB | Immunoprecipitation=IP | Paraffin Sections=PS | Cellular Staining=CS | Southern Hybridization=SH

AMERICAN ASSOCIATION FOR CANCER RESEARCH SCIENTIFIC CONFERENCES: 1993-1994

APRIL 13-17, 1993
Genetic Control of Cell Growth
Laureates Conference
General Motors
Cancer Research Foundation
Chairpersons: Leland H. Hartwell, Seattle, WA; Peter K. Vogt, Los Angeles, CA; George F. Vande Woude, Frederick, MD
San Luis Hotel, Galveston, TX

MAY 19-22, 1993
84th Annual Meeting
Chairperson: Michael B. Sporn, Bethesda, MD
Orange County Convention Center, Orlando, FL

OCTOBER 17-21, 1993
Cell Death and Cancer
Chairperson: Alan R. Eastman, Hanover, NH
Chatham Bars Inn, Chatham (Cape Cod), MA

NOVEMBER 7-11, 1993
Molecular Approaches to Cancer Immunotherapy
Chairperson: Ralph A. Reisfeld, San Diego, CA
Grove Park Inn, Asheville, NC

NOVEMBER 9-13, 1993
Interactions of Cancer Susceptibility Genes and Environmental Carcinogenesis
Joint Meeting with International Agency for Research on Cancer
Chairpersons: Frederick P. Li, Boston, MA, and Ruggero Montesano, Lyon, France
IARC, Lyon, France

DECEMBER 5-9, 1993
Cell Signalling and Cancer Treatment
Joint Meeting with British Association for Cancer Research and European Organisation for Research and Treatment of Cancer (PAM Group)
Chairpersons: Garth Powis, Tucson, AZ; Paul Workman, Glasgow, Scotland
El San Juan Hotel, San Juan, PR

JANUARY 17-22, 1994
Risk Assessment in Environmental Carcinogenesis
Chairpersons: Philip C. Hanawalt, Stanford, CA; James A. Swenberg, Chapel Hill, NC
Whistler Resort and Conference Center, Whistler, B.C., Canada

JANUARY 31-FEBRUARY 5, 1994
Molecular Genetics of Progression and Metastasis
Chairperson: Lance A. Liotta, Bethesda, MD
Big Sky Resort, Big Sky, MT

FEBRUARY 19-24, 1994
Genomic Instability and Cancer
Chairpersons: Thea D. Tlsty and Lawrence A. Loeb
Banff Springs Hotel, Banff, Alberta, Canada

MARCH 5-11, 1994
Growth Factors, Development, and Cancer
Joint Meeting with Friedrich-Miescher Institut
Chairpersons: Harold L. Moses and Bernd Groner
Congress Center, Interlaken, Switzerland

APRIL 10-13, 1994
85th Annual Meeting
Chairperson: Karen S.H. Antman, Boston, MA
Moscone Center, San Francisco, CA

AACR members will receive brochures on the above special conferences as soon as they are available. Nonmembers should call or write:

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)

COVER LEGEND



In this issue we pay tribute to R. Wayne Rundles, one of the early pioneers in the chemotherapy of cancer and a role model for current and future generations of clinicians. During a long career, which extended from 1945 until his death from prostate cancer in 1991, Dr. Rundles not only engaged in a broad range of clinical practice at Duke University School of Medicine but also played a prominent role in national programs and policies. He was a leader in formulating and guiding the clinical activities of various national programs of cancer management and was an influential member of the National Board of the American Cancer Society (ACS).

Dr. Rundles was born in Urbana, IL, in 1911. He received the M.B. from DePauw University in 1933, the Ph.D. from Cornell University in 1937, and the M.D. from Duke University in 1940. After residencies in medicine at the University of Michigan, he joined Duke University School of Medicine in 1945, where he became Professor of Medicine in 1957 and attained emeritus status in 1981. Dr. Rundles was elected to membership in Phi Kappa Phi and Alpha Omega Alpha. He held memberships in many professional associations and was Chairman of the Southeastern Cancer Chemotherapy Study Group (1956–1966), Secretary (1962–1975) and President (1967) of the American Society of Hematology, and a member of numerous ACS committees and task forces. In addition, he was an Honorary Life Member of the National Board of the ACS and served as its President (1977–1978). He was also President of the Society's Durham chapter from 1988 until his death.

Dr. Rundles' interests in clinical medicine and cancer included neurology, diabetes, pernicious and hereditary anemias, plasma cell myeloma, acute and chronic leukemias, lymphoma, gout, and hyperuricemia. He was also interested in the study of allopurinol. The chemotherapy of cancer represented his major interest, and much of his voluminous bibliography was devoted to studies of the hematological manifestations of cancer of the prostate, Hodgkin's disease, lymphomas, and leukemias and how these could be quantitated to measure clinical remissions to chemotherapy. Among other special interests were documenting remissions to urethan, triethylenemelamine, and other alkylating agents in patients with multiple myelomas; the effects of cyclophosphamide in the treatment of malignant lymphomas and ovarian and other epithelial cancers; and the relative sensitivity of lymphoid and myeloid leukemias to chlorambucil and busulfan.

He provided the clinical testing of a series of thiopurines and other chemotherapeutic and immunosuppressive agents produced by Nobel Laureates George H. Hitchings and Gertrude B. Elion. Dr. Rundles and his colleagues at Duke were major clinical collaborators of this productive group. His colleagues and students keenly appreciated his meticulous clinical and laboratory measurements, which set a high standard for quantitative clinical research in hematology and oncology. For Dr. Rundles, each patient represented a unique clinical research project from which the attentive observer could learn to help the patient and eventually humanity. For example, when allopurinol was being tested for its antileukemic properties in humans, it showed none. However, when the serum (and urine) uric acid was seen to fall sharply, he was quick to pursue a new treatment for gout, which led to the first therapy that dissolved troublesome tophaceous gouty deposits.

A scholarly scientist, Dr. Rundles used all of his wits to identify clinical problems and reduce them to pieces that could be resolved in the laboratory. Clinicians could pick up the hospital chart of one of Dr. Rundles' patients and recognize the intelligent organization, the quantitative measurement of key items, and the clear expression of the patient's history and the clinical and laboratory findings. His splendid literary skills were especially evident in a textbook on hematology [W. J. Williams, E. Beutler, A. J. Erslev, and R. W. Rundles (eds.), *Hematology*, New York: McGraw-Hill Book Co., 1972].

Other representative publications are: R. W. Rundles, Prognosis in the neurologic manifestations of pernicious anemia, Blood, *1:* 209, 1946; R. W. Rundles, M. D. Dillon, and E. S. Dillon, Multiple myeloma. III. Effect of urethane therapy on plasma cell growth, abnormal serum protein components and Bence-Jones proteinuria, J. Clin. Invest., *29:* 1243, 1950; R. W. Rundles, J. Laszlo, F. E. Garrison, Jr., and J. B. Hobson, The antitumor spectrum of cyclophosphamide, Cancer Chem. Rep. No. 16, p. 407, 1962; and R. W. Rundles, J. B. Wyngaarden, G. H. Hitchings, G. B. Elion, and H. R. Silberman, Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout, Trans. Assoc. Am. Physicians, *76:* 126, 1963.

We are indebted to John Laszlo for the information and to Margo Rundles for the photograph.

Sidney Weinhouse